Helicobacter pylori eradication rates have fallen as clarithromycin resistance spread, and proton pump inhibitor effect varies with CYP2C19 genotype. Voquezna’s regimens were built around a different acid blocker.
Vonoprazan raises gastric pH more rapidly and consistently than proton pump inhibitors, improving antibiotic stability and activity. Co-packaged with amoxicillin and clarithromycin as a 14-day oral regimen, it treats Helicobacter pylori infection in adults, and was the first potassium-competitive acid blocker approved in the U.S.
Vonoprazan has since been approved as monotherapy for erosive esophagitis and non-erosive GERD, substantially broadening the franchise beyond H. pylori. As the first U.S. P-CAB, it is the reference asset for a class positioned to challenge decades of PPI dominance.
